Inogen (INGN) 24th Annual Needham Virtual Healthcare Conference summary

Leadership and organizational changes

• Leadership team restructured with new talent to drive future growth.

• Sales organization brought in-house, ending third-party agreements to improve profitability.

• DTC channel right-sized and rebaselined, positioning for profitable growth.

• Company culture now emphasizes passion, collaboration, and bottom-up forecasting.

• Early stages of turnaround, with foundational work completed and positive momentum building.

Strategic initiatives and partnerships

• Collaboration with Yuwell includes distribution, market entry in China, and joint innovation.

• Yuwell acquired a 9.9% stake, providing $27 million for operations and R&D.

• Stationary concentrators to launch in the U.S. in the second half of 2025, with material impact expected in 2026.

• Entry into the Chinese market targeted for 2026, leveraging Yuwell’s channels.

• Focus on expanding from a single-product to a broader respiratory care and digital health company.

Product development and pipeline

• Rove 4 and Rove 6 POCs launched, targeting different patient mobility needs.

• Connectivity features in new POCs are backward compatible, enabling remote support and patient engagement.

• Pipeline expansion includes digital health and connected device offerings, with more launches expected later in the year.

• Simeox airway clearance device targets a large, underserved COPD and bronchiectasis market.

• Simeox launch strategy starts with DTC cash pay, aiming for reimbursement submission in 2026.